BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.06 +0.19%
Revenue Growth %: +31.4%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +31.4%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.46, $0.31 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $875 million versus the consensus estimate of $829.31 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.95-$5.15, versus the consensus of $5.33. BioMarin Pharma sees FY2026 revenue of $3.325-3.425 billion, versus the consensus of $3.378 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Brookfield prices $600M senior notes at 5.65% due 2031
- Cematrix wins $8.8M in new contracts, bringing YTD total to $43.2M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
